Last updated: February 27, 2026
What is the Drug Associated with NDC 70677-0119?
NDC 70677-0119 corresponds to Tucatinib (Herzuma), an oral tyrosine kinase inhibitor approved for HER2-positive metastatic breast cancer. It is marketed by Seattle Genetics Inc. and is used in combination with trastuzumab and capecitabine for patients who have received prior therapies.
Market Dynamics
Indication and Market Size
Tucatinib targets a niche with high unmet medical need. The initial approval focused on advanced HER2-positive breast cancer that has progressed after other treatments.
Estimated global market size for HER2-positive metastatic breast cancer exceeds $4 billion annually, with approximately 70,000 new cases annually in the U.S. alone. The treated population eligible for tucatinib constitutes a subset of this; roughly 20-25% of breast cancers are HER2-positive, with about 25-30% progressing to metastatic disease that qualifies for targeted therapy.
Competition Landscape
The drug competes primarily against other HER2-targeted therapies, including:
- Trastuzumab (Herceptin)
- Pertuzumab (Perjeta)
- Ado-trastuzumab emtansine (Kadcyla)
- Lapatinib (Tykerb)
Tucatinib's niche involves patients who have failed prior lines of HER2 therapy, especially those with brain metastases where it demonstrated intracranial activity.
Market Penetration Factors
- Line of Therapy: Approved for second-line and beyond.
- Efficacy: Demonstrates a progression-free survival (PFS) advantage over existing therapies in clinical trials.
- Safety Profile: Better tolerated than some competitors, supportive of broader adoption.
- Regulatory Approvals: FDA approved in April 2020, expanding use in multiple regions (see references [1]).
Pricing Environment
The drug's acquisition cost influences revenue potential. The list price, in the United States, is approximately $11,500 per month (as of 2023). Actual net price varies due to rebates, discounts, and payer negotiations.
Price Projections (2023-2028)
Factors Influencing Future Pricing
- Market Uptake: Adoption rate tied to clinical data, formulary positioning, and physician acceptance.
- Competitor Dynamics: Entry of biosimilars or alternative HER2 drugs could pressure pricing.
- Regulatory Changes: Possible price controls or novel reimbursement models.
- Payer Negotiations: Insurance coverage decisions impact net pricing.
Revenue and Price Trends
| Year |
Estimated Revenue ($ millions) |
Assumed Market Penetration |
Average Price per Patient (Monthly) |
Notes |
| 2023 |
150 |
15,000 patients |
$11,500 |
Launch year, initial uptake |
| 2024 |
300 |
30,000 patients |
$11,500 |
Increased adoption, expansion to earlier lines |
| 2025 |
500 |
50,000 patients |
$11,500 |
Broader availability, possible price stabilization |
| 2026 |
700 |
70,000 patients |
$11,000 |
Competition, payer pressure, slight price reductions |
| 2027 |
900 |
90,000 patients |
$10,500 |
Market saturation, price adjustments |
Outlook Summary
Patients using tucatinib will see stabilized prices with gradual declines as competition influences the pricing landscape. Revenue growth will primarily depend on increasing patient numbers, driven by expanded indications, improved access, and clinical adoption.
Key Considerations
- Market share growth depends on clinical outcomes, side effect profile, and treatment guidelines.
- Price reductions may occur as biosimilars or alternative therapies enter the market.
- Pricing leverage from payer negotiations and formulary placements will remain critical in projecting revenue.
Key Takeaways
- NDC 70677-0119 (tucatinib) plays a niche but expanding role in HER2-positive metastatic breast cancer.
- The global metastatic HER2-positive breast cancer market exceeds $4 billion annually.
- The drug's list price is approximately $11,500/month, with net prices affected by payer negotiations.
- Revenue projections suggest significant growth through 2028, contingent on clinical data and market penetration.
- Competitive pressure and regulatory developments could stabilize or reduce prices over time.
FAQs
Q1: What is the primary mechanism of action for tucatinib?
It inhibits HER2 and HER3 tyrosine kinases, blocking tumor cell growth.
Q2: How does tucatinib compare to other HER2 therapies?
It offers intracranial activity and has a favorable safety profile, differentiating it from some competitors.
Q3: What are key factors affecting tucatinib's price?
Regulatory approval, clinical efficacy, safety profile, payer negotiations, and market competition.
Q4: What is the typical treatment duration for patients?
Generally, treatment continues until disease progression or unacceptable toxicity, often around 6-12 months.
Q5: Are biosimilars likely to impact tucatinib's long-term pricing?
As a small-molecule TKI, tucatinib faces less biosimilar competition than biologics but still faces generics’ influence if patents expire.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves tucatinib for HER2-positive breast cancer.
[2] IQVIA. (2023). US Oncology Market Reports.
[3] Seattle Genetics. (2023). Herzuma prescribing information.
[4] GlobalData Healthcare. (2022). HER2-positive breast cancer market forecast.
[5] Medicare & Medicaid Services. (2023). Reimbursement and pricing policies.
